Literature DB >> 32052576

Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.

Jia-Li Tao1, Man Luo1, Hong Sun1, Hong-Mei Zhao1, Qing-Song Sun1, Zi-Ming Huang2.   

Abstract

It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non-small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down-regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle-related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up-regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.
© 2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  AKT; PTEN; TRIM26; cell growth; non-small cell lung cancer

Mesh:

Substances:

Year:  2020        PMID: 32052576     DOI: 10.1002/kjm2.12194

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  4 in total

1.  TRIM26 positively regulates the inflammatory immune response through K11-linked ubiquitination of TAB1.

Authors:  Jian Zhao; Baoshan Cai; Zhugui Shao; Lei Zhang; Yi Zheng; Chunhong Ma; Fan Yi; Bingyu Liu; Chengjiang Gao
Journal:  Cell Death Differ       Date:  2021-05-20       Impact factor: 15.828

2.  GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction.

Authors:  Jiannan Yang; Zhongzhi Xu; William Ka Kei Wu; Qian Chu; Qingpeng Zhang
Journal:  J Am Med Inform Assoc       Date:  2021-10-12       Impact factor: 7.942

Review 3.  The Risks of miRNA Therapeutics: In a Drug Target Perspective.

Authors:  Song Zhang; Zhujun Cheng; Yanan Wang; Tianyu Han
Journal:  Drug Des Devel Ther       Date:  2021-02-22       Impact factor: 4.162

4.  A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration.

Authors:  Di Zheng; Yunlong Zhang; Yuqi Xia; Fan Cheng
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.